LAPTM4B and chronic myelogenous leukemia, BCR-ABL1 positive: Amplification of LAPTM4B, which contributes to chemotherapy resistance and recurrence of breast cancer [30, 31] and other solid tumors [32] was over-expressed in our TKI-resistant CML cases.